Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783743 | 0.86 | DRD3 (0.53) | KDM4EALDH1A1TSHRPOLBHSD17B10 | |
| SCHEMBL2782981 | 0.84 | ALDH1A1 (0.51) | KDM4EALDH1A1TSHRPOLBHSD17B10 | |
| SCHEMBL2780977 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1TSHRPOLBHSD17B10 | |
| SCHEMBL2784944 | 0.83 | ALDH1A1 (0.50) | KDM4EALDH1A1TSHRPOLBHSD17B10 | |
| SCHEMBL2784258 | 0.83 | DRD2 (0.56) | KDM4EALDH1A1TSHRPOLBTDP1 | |
| SCHEMBL2097587 | 0.81 | KDM4E (0.65) | KDM4EALDH1A1TSHRPOLBHSD17B10 | |
| SCHEMBL16731500 | 0.80 | SMN1; SMN2 (0.53) | KDM4EALDH1A1TSHRPOLBTDP1 | |
| SCHEMBL2802128 | 0.80 | KDM4E (0.48) | KDM4EALDH1A1TSHRPOLBHSD17B10 | |
| SCHEMBL4256755 | 0.80 | KDM4E (0.63) | KDM4EALDH1A1TSHRPOLBHSD17B10 | |
| SCHEMBL10819397 | 0.79 | CHRNA7 (0.53) | KDM4EALDH1A1TSHRPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-2220083-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170174639-A1 | EIS INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2017-06-22 | — | — | US | disclosed |
| WO-2017083242-A1 | INHIBITORS OF SUPPRESSION OF TUMORIGENCITY 2 (ST2) AND METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2016006975-A2 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2016-01-14 | — | — | WO | disclosed |
| US-8785486-B2 | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785486-B2 | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110105493-A1 | HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-7915405-B2 | 2,4-disubstituted-5-aminocarbonyl-1,3-thiazole derivatives for therapeutic agent of antiinflammatory disease, method thereof for preparation, therapeutic agent for antiinflammatory disease induced by SPC activity containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-03-29 | — | — | US | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-20100145043-A1 | 2,4-Disubstituted-5-Aminocarbonyl-1,3-Thiazole Derivatives For Therapeutic Agent Of Antiinflammatory Disease, Method Thereof For Preparation, Therapeutic Agent For Antiinflammatory Disease Induced By SPC Activity Containing The Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-06-10 | — | — | US | disclosed |
| US-7642267-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| WO-2009062676-A2 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2008-09-18 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7166572-B1 | Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166572-B1 | Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | KDM4E 1996/4885ALDH1A1 470/4885TSHR 953/4885 |
| US-20170174639-A1 | EIS INHIBITORS | ABCC1, ATP5ME, ABCG2 | KDM4E 3294/4885ALDH1A1 819/4885TSHR 3072/4885 |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | KDM4E 1996/4885ALDH1A1 470/4885TSHR 953/4885 |
| US-20100145043-A1 | 2,4-Disubstituted-5-Aminocarbonyl-1,3-Thiazole Derivatives For Therapeutic Agent Of Antiinflammatory Disease, Method Thereof For Preparation, Therapeutic Agent For Antiinflammatory Disease Induced By SPC Activity Containing The Same | HRH4, TSLP, IL1R1 | KDM4E 2666/4885ALDH1A1 965/4885TSHR 1216/4885 |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRIA2 | KDM4E 1371/4885ALDH1A1 2825/4885TSHR 320/4885 |
| US-20110105493-A1 | HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | KDM4E 2230/4885ALDH1A1 670/4885TSHR 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.